
The Intravenous (IV) Solutions Manufacturing Project is a promising investment in the pharmaceutical sector, aimed at producing and packaging high-quality IV solutions such as Dextrose, Ringer’s Lactate, Sodium Chloride, Normal Saline, and other solutions used to replenish fluids and nutrients, facilitating the effective and safe delivery of medications intravenously.
This project holds significant importance due to its pivotal role in supporting the healthcare system and providing essential therapeutic solutions that help stabilize critical medical conditions, including dehydration, fluid loss, and mineral imbalances.
The increasing demand for IV solutions, driven by the continuous expansion of healthcare services and the rising number of hospitals and medical centers, makes this project a lucrative investment with high growth potential.
Furthermore, establishing a specialized IV solutions manufacturing facility enhances pharmaceutical security and reduces dependence on imports, opening opportunities for local and regional expansion, especially given the ongoing need for these products across various healthcare facilities and institutions.
In 2023, the global market for IV solutions was estimated at USD 12.9 billion, increasing to USD 13.9 billion in 2024. Forecasts indicate significant growth over the coming years, reaching USD 29.6 billion by 2034, with a compound annual growth rate (CAGR) of 8% during the period 2025–2034. This growth is driven by several key factors, including the increasing prevalence of chronic diseases, rising rates of infectious diseases, greater health awareness, and government initiatives encouraging private sector investment in healthcare to alleviate the burden on public services and address the growing population.
Setting up an IV solutions manufacturing facility in Saudi Arabia represents a strategically profitable investment, given its importance in strengthening the healthcare system and supporting the goals of Vision 2030, which focuses on developing the healthcare sector and reducing dependency on imported pharmaceuticals.
With a growing population and increasing demand for medical services, there is an urgent need for domestic IV solution production to enhance pharmaceutical security and reduce reliance on external sources. Furthermore, the project aligns with the Kingdom’s efforts to localize pharmaceutical industries and establish Saudi Arabia as a regional leader in healthcare and drug manufacturing.
Currently, the IV solutions market in Saudi Arabia is estimated at SAR 41.3 million, with projections indicating growth to SAR 53.7 million by 2032, reflecting rising local demand and the strategic importance of domestic production.
Get a Feasibility Study